AI assistant
IMUGENE LIMITED — Director's Dealing 2020
Aug 4, 2020
65124_rns_2020-08-04_7cb08c05-bb53-44a2-bba8-959b588527d3.pdf
Director's Dealing
Open in viewerOpens in your device viewer
ASX Announcement
==> picture [116 x 42] intentionally omitted <==
CEO and Managing Director increases shareholding following exercise of options
Sydney, Australia, 5 August 2020 : Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company is pleased to advise that our CEO and Managing Director, Leslie Chong has exercised 27 million options at an exercise price of $405,000.
On behalf of the Board, I wish to express our thanks to Leslie for her confidence & significant personal investment in the Company
Mr Paul Hopper
Executive Chairman
Release authorised by the Executive Chairman
IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM [email protected]